-
Exercise Interventions for Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review
The Growing Burden of MASLD in Children The prevalence of MASLD is significantly higher among children with obesity, affecting about one in four obese children. The condition is more common…
-
Nanjing Drum Tower Hospital Team Unveils the Virological and Immunological Characteristics of HBeAg-Positive Chronic Hepatitis B Patients with Low HBs
Recently, a research team from Nanjing Drum Tower Hospital, affiliated with Nanjing University Medical School, published a study in the high-impact journal Alimentary Pharmacology & Therapeutics (Impact Factor: 6.63) titled…
-
DORA Trial: Chemotherapy-Free Maintenance in Platinum-Sensitive aTNBC
The Phase II DORA study, published in April 2024, evaluated the efficacy of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (aTNBC).…
-
ASCO GU 2025 | Dr. Kan Gong & Dr. Eric Jonasch Discuss New Strategies and Future Perspectives in Kidney Cancer Treatment (Part II)
Clear cell renal cell carcinoma (ccRCC) is closely associated with dysregulation of the VHL pathway, leading to the overexpression of HIF-2α and activation of multiple oncogenic pathways. Targeting HIF-2α with therapies such as belzutifan has provided new hope for patients with VHL syndrome and even broader applications in kidney cancer treatment. At this year’s ASCO…
-
KEYNOTE-522: Pembrolizumab Improves Event-Free Survival in Early-Stage TNBC
The KEYNOTE-522 trial, published in May 2024, highlights how pembrolizumab combined with chemotherapy improves event-free survival (EFS) in early-stage triple-negative breast cancer (TNBC), particularly across Residual Cancer Burden (RCB) categories.…
-
The RIGHT Choice Trial: Ribociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The RIGHT Choice trial, published in August 2024, evaluated the efficacy of ribociclib plus endocrine therapy (ET) versus combination chemotherapy (CT) as a first-line treatment in premenopausal women with clinically…
-
Rebecca Dent and the IMpassion132 Trial: Investigating Immunotherapy in Rapidly Relapsing TNBC
The IMpassion132 phase III trial, published in July 2024, explored the impact of atezolizumab combined with chemotherapy for patients with rapidly relapsing, unresectable locally advanced or metastatic triple-negative breast cancer…
-
Emerging Biomarkers in Combination Therapy: Advancing Immunotherapy Strategies for Lung Cancer
Immuno-oncology (IO) has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), providing durable responses and survival benefits across different disease stages. The success of immune checkpoint inhibitors (ICIs), including PD-(L)1 and CTLA-4 inhibitors, has paved the way for dual immune checkpoint blockade (ICB) therapy, aiming to enhance antitumor immunity. While clinical trials such…
Connecting Medical Expertise through Media